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INTRODUCTION: A Cochrane review of seven randomised trials (N¼1571) comparing surgery and primary endocrine therapy (PET)
(oestrogen receptor (ER) unselected) shows no difference in overall survival (OS). We report outcome of a large series with
ER-positive (ERþ) early invasive primary breast cancer.
METHODS:Between 1973 and 2009, 1065 older (X70 years) women (median age 78 years (70–99)) had either surgery (N¼449) or
PET (N¼616) as initial treatment.
RESULTS:At 49-month median follow-up (longest 230 months), the 5-year breast cancer-specific survival (BCSS) and OS were 90 and
62%, respectively. Majority (74.2%) died from causes other than breast cancer. The rates (per annum) of local/regional recurrence
(o1%) (following surgery), contralateral tumour (o1%) and metastases (o3%) were low. For patients on PET, 97.9% achieved
clinical benefit (CB) at 6 months, with median time to progression of 49 months (longest 132 months) and significantly longer BCSS
when compared with those who progressed (Po0.001). All patients with strongly ERþ (H-score 4250) tumours achieved CB and
had better BCSS (Po0.01). Patients with tumours having an H-score 4250 were found to have equivalent BCSS regardless of
treatment (surgery or PET; P¼0.175), whereas for those with H-score p250, surgery produced better outcome (Po0.001).
CONCLUSION: Older women with ERþ breast cancer appear to have excellent long-term outcome regardless of initial treatment.
Majority also die from non-breast cancer causes. Although surgery remains the treatment of choice, patients with ER-rich (H-score
4250) tumours tend to do equally well when treated by PET. This should be taken into account when therapies are considered.
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Advancing age is one of the major risk factors for breast
cancer development, with a risk of 1 in 208 at the age of 40 years
increasing to 1 in 16 at the age of X70years (Jemal et al, 2009),
resulting in 33% of breast cancer occurring after 70 years of age
(Office for National Statistics, 2005; Cancer Research UK, 2009).
The incidence of breast cancer in older women is increasing
worldwide and is expected to rise more in the upcoming years, as a
result of longer lifespan. There has been minimal representation of
older patients in most clinical trials and management-related
studies, making the establishment of clear management guidelines
difficult. More than 60% of women over the age of 70 years have at
least one significant co-morbid condition (angina or myocardial
infarct in 25.7%, congestive heart failure in 25.0%, history of stroke
in 16.2% and rheumatological conditions in 65.8%, as shown in a
study; Fleming et al, 1999) that could limit their life expectancy
or produce negative impact on their quality of life. The number of
co-morbidities has also been shown to be inversely proportional to
life expectancy (Fleming et al, 1999).
Given the limited life expectancy and senility-associated
co-morbidities, surgery may not be appropriate for some older
women, or they may not be willing to have surgery because of their
associated social problems. Primary endocrine therapy (PET) then
becomes a viable option. A recently published audit of breast
cancer management showed that 40% of women over 70 years of
age were treated with PET in the United Kingdom (Wyld et al,
2004). Therefore, it is of prime importance in the current situation
to know the efficacy of PET in comparison with surgery and also to
identify the group of patients whose treatment outcome from PET
may be comparable with that from surgery.
A recent Cochrane review of seven randomised trials (N¼1571)
comparing surgery and PET in women X70 years of age,
unselected for oestrogen receptor (ER) status, did not show any
difference in the two treatment arms in terms of overall survival
(OS) (Hind et al, 2007). Older patients are more likely to die
from co-morbidities other than breast cancer (Diab et al, 2000);
hence, OS might not be the actual predictor of disease outcome.
The patients with ER-positive tumours respond well to endocrine
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stherapy, which is an important factor and should have been taken
into account for such comparison.
Given the background discussed above in terms of biology and
co-morbidities impacting on the management approach and
outcome, and the lack of high-level large-scale randomised
evidence, this study aimed to: (1) describe and analyse the
long-term clinical outcome of older women with ER-positive early
operable primary breast cancer treated in a single centre regard-
less of primary treatment; and (2) compare surgery vs PET in
this cohort.
MATERIALS AND METHODS
As part of an ongoing research programme on early operable
primary breast cancer in older women, a database was established,
including 1709 patients, diagnosed and treated at the Nottingham
Breast Unit from 1973 to 2009. The patients were first identified
from the archive of paper records (before 1987, N¼240) and a
computerised database (since 1987, N¼1469) of the Histopathology
Department, with clinical information subsequently confirmed in
clinical records. All patients were females X70 years of age, who
had either ductal carcinoma in situ or invasive early operable
primary breast cancer p5cm of clinical size without evidence of
distant metastases at the time of diagnosis.
All patients were managed in a dedicated Primary Breast Cancer
Clinic for Older Women (the Clinic) following the same clinical
guidelines at any time point. For the patients identified in this data
set, data were retrospectively collected from case notes, including
detailed information of the clinical course of the disease from the
date of diagnosis till death or last follow-up. The data set was based
on the variables recorded for the primary breast cancer series used
to derive the Nottingham Prognostic Index (NPI) (Haybittle et al,
1982; Blamey, 1996) for patients treated by surgery. For patients
on nonoperative therapy (predominantly PET), clinical responses
at 6 months, progression status and time to progression were
recorded for all lines of endocrine therapy and best response
recorded only for first-line PET.
Patients
Out of the established data set as described above, all women with
ER-positive (defined in the section on tumour characteristics)
invasive carcinoma treated by primary surgery (with and with-
out adjuvant endocrine therapy) (N¼449) or PET (N¼616) were
included in this study. This study has included some patients
recruited into two small, previously reported, randomised
controlled trials comparing primary tamoxifen vs mastectomy as
long as they had ER-positive tumours (Willsher et al, 1997;
Chakrabarti et al, 2010). For the analysis of response to PET, only
patients with response status at 6 months available (first line
N¼541, second line N¼209 and third line N¼62) were included,
as per British Breast Group recommendations (Group, 1974).
Treatment protocol
The treatment protocol had been changing over the period because
of evolving clinical evidence and unit policy. Because of the focus
of this study, the management protocols given below describe the
unit policy only for patients with ER-positive tumours in each
period of time.
1973–1999 All patients with a confirmed diagnosis of breast
cancer were given the choice of surgery or PET. Patients
undergoing surgery had options of mastectomy or breast
conservation (wide local excision (WLE)) as appropriate. Axillary
surgery was only considered when there were clinically palpable
axillary lymph node(s). The patients who underwent WLE were
given no further treatment, adjuvant endocrine therapy with or
without adjuvant radiotherapy, depending on the clinical judge-
ment of the clinician, based on tumour grade, margin status,
degree of ER positivity and nodal status if available.
For patients who opted for PET, tamoxifen was the drug of
choice. Patients with contraindications to tamoxifen (e.g., thrombo-
embolic risk) were then offered a nonsteroidal aromatase inhibitor
(AI) such as anastrozole, since it became available in 1995. When
patients progressed on first-line PET, a number of treatment
options were considered, depending on the patient’s choice,
fitness, previous response to endocrine therapy and development
of distant metastases, including surgery, further endocrine therapy
or primary radiotherapy.
2000–2009 The treatment protocol was more structured and all
cases were discussed at a multidisciplinary team meeting before
the patients were seen in the Clinic (which has become a combined
surgical/oncology facility during this period).
All patients with a confirmed diagnosis of breast cancer were
recommended to have surgery (mastectomy or WLE as appro-
priate). Axillary surgery (four-node sampling with introduction
of blue-dye sentinel node biopsy recently; or level III axillary
clearance for node-positive cases proven by ultrasound-guided
core biopsy preoperatively) became part of standard surgery.
Intact breast irradiation was normally given following WLE unless
the patient was on adjuvant endocrine therapy. Post-mastectomy
chest wall irradiation was normally given if the tumour had two
out of the following three features: grade 3, positive nodal status
and vascular invasion. Patients having tumours with an NPI of
X3.4 (moderate and poor prognostic groups) received adjuvant
endocrine therapy (using tamoxifen that has subsequently been
replaced by a nonsteroidal AI). Those having tumours with an NPI
between 3 and 3.4 (good prognostic group) were given the option
of no adjuvant endocrine therapy or tamoxifen. Those belonging to
the excellent prognostic group (NPI o3) did not receive any
systemic therapy.
The patients who refused or were deemed unfit for surgery were
then given PET as described above.
Assessment of co-morbidities There was no formal tool for
co-morbidity assessment used in the Clinic. However, all patients
were assessed by a single surgeon with an interest in the
management of older women with primary breast cancer. During
the most recent decade, the Clinic has evolved into a combined
surgical/oncology facility, supported by two breast cancer nurses
in order to further improve such assessment. A pilot study to
evaluate a cancer-specific comprehensive geriatric assessment
(CGA) tool has also commenced recently.
Follow-up
All patients were followed up in the Clinic. Patients treated
surgically were followed-up on a yearly basis or anytime they
required consultancy for any new finding. Patients on PET were
followed-up at 6-week time after commencement of therapy, and
then 3- and 6-month intervals thereafter or anytime as required.
Response to PET was assessed clinically by callipers using
International Union Against Cancer (UICC) criteria (Hayward
et al, 1977), with adherence to the British Breast Group
recommendations (Group, 1974).
Tumour characteristics
Pathological information was based on needle core biopsies for all
patients, as reported by a single dedicated team of pathologists
following the same guidelines at any time point. Positive ER status
was defined in majority of cases by histochemical score (H-score)
X50, using immunohistochemistry as previously described
(Nicholson et al, 1986). In the earlier period, charcoal-coated
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smethod was used for ER assessment in a few cases (N¼3) and
positivity was defined as 5fmol of cytosolic protein equivalent to
Allred score of 5 (Shousha, 2008).
The grade of the tumour and the axillary stage were recorded
from histopathology reports of surgical specimens: grade defined
as the cumulative score of nuclear pleomorphism, tubule forma-
tion and mitotic count by the modified Scarf-Bloom-Richardson
(SBR) criteria (Elston and Ellis, 1991) and categorised as grade
1–3, and stage defined by the quantitative score of positive axillary
lymph nodes (LNs): stage 1¼0 LN, stage 2¼1–3 LNs and stage
3¼X4 LNs positive.
Outcome variables
Survival, metastases and contralateral tumour development
were recorded for all patients. Breast cancer-specific survival
(BCSS) was defined as the time from the date of diagnosis till
death from breast cancer. Overall survival was defined as the time
from the date of diagnosis till death regardless of cause. The causes
of death were categorised into breast cancer deaths, defined as
breast cancer as the first cause of death on the certificate, and non-
breast cancer deaths, defined as the registered non-breast cancer
cause or if the women with unknown causes of death died within
1 year of their last follow-up without clinical evidence of metastases.
The causes of deaths were recorded from the case notes and
supplemented by information from the general practitioners (GP)
for those patients who were discharged back to GP’s care because
of their preference. This included patients who subsequently died
outside Nottingham following their discharge. A total of 41 (3.8%)
patients were completely lost from follow-up and were not
included in the analysis of survival.
Metastases were defined as the appearance of tumour at a
distant site (including contralateral axillary LN, ipsilateral and
contralateral supraclavicular LN, bones, liver, lung and so on) and
time to metastases was calculated from the date of diagnosis of the
primary tumour till the appearance of metastases.
Contralateral tumour referred to the appearance of a new
primary in the other breast, and time to contralateral tumour was
calculated in the same way as described above.
Patients treated by surgery had additional outcome variables
recorded. Local recurrence was defined as the appearance of
tumour in the ipsilateral breast after WLE or in the mastectomy
flap. Regional recurrence was defined as the appearance of tumour
in the ipsilateral axilla. Time to local or regional recurrence was
calculated from the time of surgery.
For patients on PET, additional outcome variables were
related to the response to therapy, assessed by the UICC criteria
(Hayward et al, 1977), and time to progression was defined as
the time from the commencement of the endocrine agent till the
tumour progressed. Clinical benefit (CB) was defined as the
achievement of complete response (CR), partial response (PR) or
stable disease (SD) for at least 6 months from the commencement
of therapy and objective response (OR) was defined as the
achievement of CR or PR for at least 6 months from the
commencement of therapy.
Statistical methods
The statistical Package for Social Sciences (SPSS version 16.0, SPSS
Inc., Chicago, IL, USA) was used as the data analysis tool.
Statistical significance was defined by P-value o0.05. Kaplan–
Meier was used to analyse survival and other time-dependant
variables, log-rank and Wilcoxon tests were used as appropriate.
Standard error (s.e.) and 95% confidence interval (CIs) in terms of
time were based on Kaplan–Meier. Given the long timespan of the
study time, dependant variables were compared at years 5 and 10,
using Kaplan–Meier and life table.
RESULTS
Patient and tumour characteristics
A total of 1065 women with ER-positive tumours had been
diagnosed and treated with early operable primary breast cancer
with a median follow-up of 49 months (endocrine therapy 41
months (longest 202 months), surgery 57 months (longest 230
months)). The median age of the study population was 78 years
(range 70–99). Women who received PET were relatively older
with a median age of 81 years (range 70–99) when compared with
75 years (range 70–90) for patients who had surgery. The majority
of women had strongly ER-positive tumours, with an H-score
4200 in 54.7% (Table 1). Increasing age was associated with
strongly ER-positive tumours (P-value o0.01). The median
tumour size was 2.8cm (range 0–5cm) and most women had
larger tumours, 42.0cm (65.9%) of clinical size (Table 1). Patients
in the PET group had larger tumours with a median size of 3.0cm
(o2cm¼25%, 42cm¼75%), whereas in the surgery group the
median size was 2.3cm (o2cm¼46%, 42cm¼56%; P-value
o0.001). The grade, histological types and axillary stage of the
disease reported on surgical specimens are summarised in Table 1.
Most patients had grade 2 tumours (51.5%) and stage 1 (61.2%)
disease. Ductal carcinoma of no special type (NST) was the most
common histological type (59.1%), followed by tubular mixed and
lobular types.
Treatment pattern
Over these three decades, a larger proportion of women received
PET (57.8% (N¼616)) when compared with surgery (42.2%
(N¼449)). Patients who had primary endocrine therapy tended to
be older and had larger tumour size, whereas the distribution of
ER positivity was similar (Table 1). Specifically during the period
of 1973–1999, 301 and 128 patients had PET and surgery,
respectively. Recently (2000–2009), 315 and 321 patients were
treated by PET and surgery, respectively. The details of surgery
and adjuvant therapy are summarised in Table 1. The majority of
patients had adjuvant endocrine therapy (75.9% (N¼341)).
Tamoxifen was the most commonly used first-line agent for
patients on PET (69.3% (N¼427)), followed by anastrozole.
Outcome
Whole series Survival: The 5-year OS and BCSS were 62 and 90%,
respectively, regardless of the treatment given. Most of the women
in the cohort died from non-breast cancer causes (74.2%); this
proportion further increased to 82.9% in the age group X80 years.
The data for causes of death are presented in Table 2.
Surgery group Local and regional recurrence: The overall rates of
local and regional recurrences were low, at 4.7 and 3.1%,
respectively (Table 3). There was no significant difference in the
rate of and time to local recurrence following mastectomy and
WLE (log-rank P-value¼0.709) and there was no significant
difference of the rate of and the time to regional recurrence in the
patients undergoing axillary surgery when compared with those
who did not have any axillary surgery (log-rank P-value¼0.732).
PET group First line: A total of 616 women were put on PET; 541
patients had their response at 6 months available for analysis and 5
women (0.9%) did not tolerate the therapy (two were on
anastrozole and three on tamoxifen). The overall CB was 97.9%
with 2.1% (N¼11) progression within 6 months. The response at 6
months is described in Table 4. Eventually, 519 women achieved
CR, PR or SD (CR (N¼161 (31%)), PR (N¼182 (35.1%)) or SD
(N¼176 (33.9%)) and the overall eventual progression rate was
45.0% (N¼244). The median time to progression was 49 months
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s(range 4–132 months). The median duration of CB was 30 months
with the longest duration of 180 months (range 7–180 months). A
total of 275 patients needed to change their first line of therapy
because of eventual progression of disease or intolerance, 90.4%
(N¼254) were switched to second line of endocrine therapy,
whereas 7.1% (N¼20) had surgery and 2.5% (N¼7) had primary
radiotherapy.
Second line: Out of the 254 patients on second-line PET, the
response at 6 months was available for 209 patients (Table 4). Most
of the tumours remained stable (55.0%) and the overall CB was
95.7% with an eventual progression rate of 51.9%. The median
time to progression was 30 months (range 3–144 months) and the
median duration of CB was 20 months (range 7–144) months). A
total of 117 women needed third-line therapy, 74.4% (N¼87) were
switched to third-line endocrine therapy, 14.5% (N¼17) had
surgery, 9.4% (N¼11) had primary radiotherapy whereas 1.7%
(N¼2) had a combination of endocrine therapy and radiotherapy.
Third line: A total of 87 women were put on third-line PET and
the response at 6 months was available in 62 women (Table 4). The
CB rate at 6 months was 87.1% (N¼54) with a median time to
progression of 20 months (range 1–52 months) and a median
duration of CB of 16 months (range 7–85 months).
Association of response to PET with H-score The women who
achieved CB at 6 months had statistically significantly better
BCSS when compared with those who progressed, although the
number of the latter was small (Figure 1A). Patients with strongly
ER-positive tumours (H-score 4250) responded well to PET and
all of them achieved CB at 6 months (Table 4). The same patients
had significantly better BCSS, with the rate of 93% at 10-year
when compared with 71% if the H-score was p250 (log-rank
P-value¼0.012; Figure 1B).
Surgery vs PET
Contralateral tumours and metastases The overall rate of
contralateral tumour development was 2.1% (surgery¼3.4% and
PET¼1.2%, P-value o0.01) and the overall rate of metastases was
10.5% (surgery¼9.2% and PET¼11.4%, P-value¼0.143). The
data for contralateral tumour and metastases development are
summarised in Table 3.
BCSS The 5-year BCSS was 84 and 95% in the PET and surgery
groups, respectively (log-rank P-value o0.001; Figure 2). When
comparing with those receiving PET, the patients having surgery
had better BCSS in the age group o80 years (5-year BCSS¼83 vs
95% in PET vs surgery groups respectively, log-rank P-value
o0.001), whereas in women X80 years there was no significant
difference observed between the treatment arms (5-year BCSS¼88
vs 92% in PET vs surgery groups, log-rank P-value¼0.800;
Figure 2). Similar results were observed when only patients who
had adjuvant endocrine therapy following surgery were compared
with those having PET.
It was found that the patients who had strongly ER-positive
tumours (H-score 4250) had the same BCSS regardless of
treatment (5-year BCSS¼93 vs 95% in PET vs surgery groups,
log-rank P-value¼0.715), whereas if H-score was p250, surgery
appeared to produce better outcome (5-year BCSS¼84 vs 95% in
PET vs surgery groups, log-rank Po0.001; Figure 2).
DISCUSSION
The results of the study showed a preponderance of relatively
lower-grade and ER-rich tumours in older women. Across a period
of more than three decades, mastectomy was the most common
surgical procedure done and adjuvant endocrine therapy was given
in the majority of cases regardless of the type of surgery. The rates
of local and regional recurrence, contralateral tumour develop-
ment and metastases were low. The overall response to PET
appeared excellent with 497% CB within 6 months. All women
with tumours having an H-score 4250 responded well to PET and
achieved CB at 6 months. The outcome of surgery and PET in
Table 1 Patient and tumour characteristics and treatment pattern in
older women with early operable primary breast cancer
Number
of patients
Percentage
(%)
PET,
N (%)
Surgery,
N (%)
Age (years) N¼1065 N¼616 N¼449
70–79 624 58.6 253 (41.1) 371 (82.6)
X80 441 41.4 363 (58.9) 78 (17.4)
Clinical size of tumour (cm) N¼1059 N¼612 N¼447
0 (Screen detected) 78 7.4 9 (1.5) 69 (15.4)
0.1–2 283 26.7 147 (24.0) 136 (30.4)
2.1–5 698 65.9 456 (74.5) 242 (54.1)
H-score N¼1062 N¼614 N¼448
50–100 46 4.3 27 (4.4) 19 (4.2)
101–200 435 41.0 241 (39.3) 194 (43.3)
201–300 581 54.7 346 (56.4) 235 (52.5)
Histological characteristics and treatment pattern of surgery group
Histological grade N¼431
1 84 19.5
2 222 51.5
3 125 29.0
Axillary stage N¼353
1 216 61.2
2 110 31.2
3 27 7.6
Histological types N¼445
Ductal carcinoma (NST) 263 59.1
Tubular mixed 63 14.2
Lobular carcinoma 61 13.7
Mucinous carcinoma 21 4.7
Other types 37 8.3
Types of surgery N¼449
Mastectomy 255 56.8
WLE 194 43.2
Adjuvant therapy with
mastectomy
N¼255
AdjET only 157 61.6
AdjRT only 3 1.2
AdjET+AdjRT 42 16.5
No adjuvant therapy 53 20.8
Adjuvant therapy with WLE N¼194
AdjET only 97 50.0
AdjRT only 35 18.0
AdjET+AdjRT 45 23.2
No adjuvant therapy 17 8.8
Abbreviations: AdjET¼adjuvant endocrine therapy; AdjRT¼adjuvant radiotherapy;
NST¼no special type; PET¼primary endocrine therapy; WLE¼wide local excision.
Table 2 Causes of death by age groups in older women (X70 years
of age) with early operable primary breast cancer
Breast cancer
deaths, N (%)
Non-breast
cancer deaths, N (%) Total P-value
All 105 (25.8) 302 (74.2) 407 o0.001
70–79 years 70 (34.7) ) 132 (65.3) ) 202 o0.001
o0.001
X80 years 35 (17.1) 170 (82.9) 205 o0.001
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sterms of BCSS appeared similar in women 480 years of age or in
those with tumours having an H-score 4250.
Surgery has been the standard management for early operable
primary breast cancer regardless of age and tumour biology.
The studies comparing surgery and PET in older women showed
better local control of the disease when they were surgically
treated, but none of them reported any uncontrollable local disease
in the PET arm. Furthermore, as shown in the meta-analysis of
seven randomised trials, there was no significant difference in the
OS in two treatment arms (Hind et al, 2007). Although measuring
the OS in older women has an advantage of assessing the influence
of co-morbidities, BCSS on the other hand helps to measure
tumour behaviour as it takes deaths due to breast cancer
specifically into account. Among the seven randomised trials
mentioned, with the exception of the GRETA trial, all compared
both treatment arms in terms of OS. The GRETA trial, after a
median follow-up of 80 months, did not show any difference in
BCSS between surgery and PET (Mustacchi et al, 2003).
The randomised controlled trials included in the above-
mentioned Cochrane review were unselected for ER status, with
the exception of the Nottingham II trial, which included patients
with ER-positive tumours (H-score X100; Willsher et al, 1997).
Tamoxifen was the agent used in all these trials to compare with
surgery; however, emerging evidence on AIs showed similar or
better response when compared with tamoxifen. These drugs have
the potential to produce improved outcome, including local
control, with PET. The outcomes of this cohort study are
consistent with those reported in the Nottingham II trial (selected
for ER with H-score X100 instead of X50 as in this present larger
study) in terms of CB. The CB rates at 6 months were 97 and
97.9%, respectively in the Nottingham II trial and the present study
(Willsher et al, 1997).
Although available literature suggests surgery as the standard
treatment, this approach remains questionable in older patients
with limited life expectancy, significant number of co-morbidities
and social dependency. Recently, in the United Kingdom, a
nationwide audit of the pattern of management of breast cancer
showed that 40% of older patients received PET (Wyld et al, 2004).
The concerns in the management of older patients with breast
cancer are not only the control of the disease, but also the quality
of life; hence, it is crucial to understand the criteria to select
patients who are likely to benefit from PET rather than surgery.
The Endocrine ± Surgical Therapy for Elderly women with
Mammary cancer (ESTEeM) trial was designed to answer these
questions. The trial was established in the United Kingdom aiming
to randomise women 475 years of age with ER-positive early
operable primary breast cancer to have either surgery followed by
adjuvant anastrozole or primary anastrozole as initial treatment.
Unfortunately, it was prematurely closed because of slow
recruitment.
Given the challenges in recruiting older patients into rando-
mised controlled trials, which have been the gold standard leading
to a change in practice, non-randomised, observational or even
long-term retrospective studies might be options to be considered
as the best possible evidence to set clinical guidelines for this
group of patients.
This study, a retrospective review with long-term follow-up and
large sample size, from a single centre, attempted to address this
issue. Comparatively older patients opt to have PET because of co-
morbidities, which prevent them from having surgery. The study by
Tang et al (2011) showed that patients on PET were on average 7
years older than those patients who had surgery; the related factors
were the number of co-morbidities and their own choice. This might
explain the slightly larger tumour size seen in the group of patients
treated by PET, although the distribution appears similar in both
groups in terms of the degree of ER positivity (Table 1).
As age advances, patients are less likely to die from their cancer,
with decreasing breast cancer mortality. The study by Diab et al
(2000) showed 29% of breast cancer deaths in women over 85 years
Table 4 Outcome of primary endocrine therapy (response at 6 months) in older women with oestrogen receptor-positive early operable primary breast
cancer
Response at 6 months
Line of endocrine therapy CR, N (%) PR, N (%) SD, N (%) PD, N (%) CB, N (%)
First line (N¼541) 66 (12.3) 189 (35.5) 270 (50.4) 11 (2.1) 525 (97.9)
Second line (N¼209) 46 (22.0) 39 (18.7) 115 (55.0) 9 (3.8) 200 (95.7)
Third line (N¼62) 14 (22.6) 4 (6.5) 36 (58.1) 8 (12.9) 54 (87.1)
Response at 6 months
H-score CB,* N (%) PD,* N (%)
p250 403 (97.3) 11 (2.7)
4250 121 (100) 0 (0)
Abbreviations: CB¼clinical benefit; CR¼complete response; PD¼progressive disease; PR¼partial response; SD¼stable disease. *P-value¼0.058.
Table 3 Outcome of oestrogen receptor-positive early operable
primary breast cancer in older women (X70 years of age)
Event
Overall rate
(%)
Average rate per annum
(%)
Surgery group only
Local recurrence
Whole surgery group 4.7 1.0
Mastectomy 5.1 0.9
WLE 4.2 1.4
Regional recurrence
Whole surgery group 3.1 0.5
Axillary surgery group 2.4 0.5
No axillary surgery
group
4.7 0.5
All patients
Contralateral tumour development
Whole group 2.1 0.7
Surgery±AdjET 3.4 1.0
Surgery+AdjET 2.7 1.0
PET 1.2 0.4
Metastases
Whole group 10.5 2.0
Surgery±AdjET 9.2 1.9
Surgery+AdjET 9.1 2.0
PET 11.4 2.2
Abbreviations: AdjET¼adjuvant endocrine therapy; PET¼primary endocrine
therapy; WLE¼wide local excision.
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sof age and Chapman et al (2008) showed 28% of breast cancer
deaths in the MA.17 trial. Our study showed similar findings in
that majority of deaths were because of non-breast cancer causes
and this became even more pronounced for women 480 years.
The rates of local and regional recurrences were low in our study
population, not influenced by the type of surgery. The Nottingham
II trial showed 4% of local recurrence rate at a median follow-up
of 3 years and 11% of regional recurrence in the women with
ER-positive tumours without axillary surgery. This might be
because of the influence of adjuvant endocrine therapy. The
randomised controlled trials comparing axillary surgery and no
axillary surgery in the elderly women with early operable primary
breast cancer have also shown no significant difference in outcome
(Martelli et al, 2005; Group IBCS, 2006).
Despite the fact that over half of our patients who had breast-
conserving surgery did not receive postoperative radiotherapy,
their local recurrence rates remained low, especially when they
were taking tamoxifen together as previously reported (Valassiadou
et al, 2007). This observation is also supported by a randomised
controlled trial (Hughes et al, 2004, 2010).
Advancing age seems to be associated with strongly ER-positive
tumours; Cheung et al (2008) showed that 44.4% of tumours had
H-score 4200 (the peak H-score being 200–300) and 70.3% had
480% of cells stained positive for ER in the patients 470 years of
age. This was in contrast to the peak H-score of 100–200 among
ER-positive tumours in women o70 years.
Although B10% of patients were not available for follow-up
assessment at 6 months after having been started on PET, this
remains a large series (N¼541), when compared with the
literature – even the Cochrane review of seven randomised trial
includes 1571 patients treated by either surgery or PET (Hind et al,
2007). Our study therefore provides an important contribution to
the literature in this area.
The response to PET appeared excellent for each line of therapy
with minimal rate of intolerance to therapy and considerably long
time to progression and duration of CB. The CB rate of PET in the
advanced breast cancer setting was shown to be B70%,
(Robertson et al, 1997) but in this study, which included very
rich ER early operable cancer, the response appeared superior
(497%). The response to PET appeared to be associated with the
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Figure 1 Breast cancer-specific survival of early operable primary breast cancer in older women (X70 years of age) – surgery vs primary endocrine
therapy. (A) Clinical benefit (CB) vs progressive disease (PD) at 6 months. (B) H-scorep250 vs 4250.
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Figure 2 Breast cancer-specific survival of early operable primary breast cancer in older women (X70 years of age) treated with primary endocrine
therapy. Surgery vs primary endocrine therapy – (A) whole series; (B) age group 70–79 years; (C) age group X80 years; (D) H-scoreo250; and
(E) H-scoreX250.
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sdegree of ER positivity and all those with strongly ER positive
tumours (H-score 4250) achieved CB at 6 months and had better
BCSS when compared with those who progressed at 6 months
with H-score p250. In this population with ER-rich tumours, PET
was found to produce comparable outcome as surgery in terms of
BCSS. The achievement of CB at 6 months has been demonstrated
as an indication to continue PET and patients were found to have
better survival than those who progressed early (Robertson et al,
1997; Willsher et al, 1997). This finding has a potential value in
guiding the use of neoadjuvant endocrine therapy.
Older women with ER-positive invasive early operable primary
breast cancer appear to have excellent long-term clinical outcome
regardless of initial treatment. Although surgery remains the primary
treatment of choice, patients with ER-rich tumours (H-score 4250,
a l s om o r ec o m m o n l yf o u n dw i t hi n c r e a s i n ga g e )t e n dt od oe q u a l l y
well when treated by PET. This study has focussed on the analysis
o fl o n g - t e r mo u t c o m ei nt e r m so fB C S S ,w h i c hi sar e f l e c t i o no f
tumour behaviour. Within this context, we have already demonstrated
comparable outcome between surgery and PET for patients with ER-
rich tumours. Comparison of OS is deemed inappropriate in this study
given the nonrandomised nature. However, given that most patients
die from non-breast cancer causes, affecting the OS, it would not be
difficult to appreciate the potential value of PET, especially in patients
with ER-rich tumours, as well as a number of significant co-morbidities
further shortening their life expectancy (the median time of progres-
sion on PET regardless of H-score in this study was 49 months).
With the growing elderly population, given the complexity
of their problems and the differences in biology of breast
cancer, older women with newly diagnosed primary breast cancer
deserve a more detailed work up in order to optimise their
management.
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